1. Articles in category: Drug

    1-24 of 306 1 2 3 4 ... 11 12 13 »
    1. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

      Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

      Oncotarget. 2017 Jul 04;:

      Authors: Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T

      Abstract Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.

      Read Full Article
    2. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    3. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    4. Optimization of liposomal topotecan for use in treating neuroblastoma.

      Optimization of liposomal topotecan for use in treating neuroblastoma.

      Cancer Med. 2017 May 23;:

      Authors: Chernov L, Deyell RJ, Anantha M, Dos Santos N, Gilabert-Oriol R, Bally MB

      Abstract The purpose of this work was to develop an optimized liposomal formulation of topotecan for use in the treatment of patients with neuroblastoma.

      Read Full Article
      Mentions: Treatment
    5. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      Drug Deliv Transl Res. 2017 Apr 21;:

      Authors: Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB

      Abstract Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy.

      Read Full Article
      Mentions: Treatment
    6. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Exp Biol Med (Maywood). 2017 Jan 01;:1535370217706952

      Authors: Cooper JP, Reynolds CP, Cho H, Kang MH

      Abstract Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.

      Read Full Article
    7. Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Pediatr Res. 2017 Apr 18;:

      Authors: Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N

      Abstract BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children.

      Read Full Article
    8. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Conditions :   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma Interventions :   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate Sponsors :   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting - verified April 2017

      Read Full Article
    9. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      J Control Release. 2017 Apr 12;:

      Authors: Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

      Read Full Article
    10. Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.

      Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.

      Eur J Med Chem. 2017 Feb 27;130:336-345

      Authors: Lelle M, Freidel C, Kaloyanova S, Tabujew I, Schramm A, Musheev M, Niehrs C, Müllen K, Peneva K

      Read Full Article
    11. Advances in emerging drugs for the treatment of neuroblastoma.

      Advances in emerging drugs for the treatment of neuroblastoma.

      Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75

      Authors: Berlanga P, Cañete A, Castel V

      Abstract INTRODUCTION: Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis.

      Read Full Article
      Mentions: Treatment Relapse ALK
    12. Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer Center

      Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer Center

      SAN DIEGO, March 3, 2017 /PRNewswire/ -- Lin BioScience has licensed the intellectual property portfolio for a novel inhibitor of CDC7 kinase. Under this worldwide exclusive licensing agreement with Columbia University and Memorial Sloan Kettering Cancer Center, Lin BioScience plans to...

      Read Full Article
    13. Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Oncotarget. 2017 Feb 08;:

      Authors: Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S

      Abstract Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes.

      Read Full Article
      Mentions: Treatment MYCN
    14. Neuroblastoma treatment in the post-genomic era.

      Neuroblastoma treatment in the post-genomic era.

      J Biomed Sci. 2017 Feb 08;24(1):14

      Authors: Esposito MR, Aveic S, Seydel A, Tonini GP

      Abstract Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics.

      Read Full Article
      Mentions: Treatment ALK MYCN
    15. GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

      GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

      J Cell Physiol. 2017 Feb 01;:

      Authors: Gholamin S, Miezaei H, Razavi SM, Hassanian SM, Saadatpour L, Masoudifar A, ShahidSales S, Avan A

      Abstract Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy.

      Read Full Article
      Mentions: Immunotherapy
    16. Dual ALK and CDK4/6 inhibition demonstrates on-target synergy against neuroblastoma.

      "The combination of Ribociclib, a dual inhibitor of cyclin-dependent kinase (CDK) 4 and 6, and the ALK inhibitor Ceritinib demonstrated higher cytotoxicity (p=0.008) and synergy scores (p=0.006) in cell lines with ALK mutations as compared to cell lines lacking mutations or alterations in ALK. Compared to either drug alone, combination therapy enhanced growth inhibition, cell cycle arrest, and caspase-independent cell death. Combination therapy achieved complete regressions in neuroblastoma xenografts with ALK-F1174L and F1245C de novo resistance mutations, and prevented the emergence of resistance. Murine Ribociclib and Ceritinib plasma concentrations were unaltered by combination therapy.  This preclinical ...

      Read Full Article
      Mentions: ALK
    17. Resistance of stem-like cells from neuroblastoma cell lines to commonly used anticancer drugs.

      "Neuroblastoma lines SK-N-BE and SK-N-SH had 2% and 8% cells expressing CD133 respectively, while SH-SY-5Y had no CD133 expressing cells. CD133 + cells showed significant resistance to all four drugs in the MTT assay as well as the PI/Annexin binding assay compared to CD 133 - cells. This study suggests that CD133+ cells in neuroblastoma cell lines are more resistant to conventional anti-cancer drugs compared to CD133- cells. Targeting these stem-like cell populations could lead to development of more effective treatment for neuroblastoma."

      Read Full Article
      Mentions: Relapse
    18. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature

      "The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment. These proteins have an essential role in gene transcription regulation by binding acetylated lysine residues on histone tails, activating gene transcription. BET inhibitors have been tested in preclinical models including pediatric malignancies and several adult clinical trials are ongoing."

      Read Full Article
      Mentions: Treatment
    19. Implantable Chemotherapy-Loaded Silk Protein Materials for Neuroblastoma Treatment.

      "Furthermore, intra-tumor delivery decreased the maximum plasma concentration compared to IV delivery, reducing systemic exposure and possibly reduing long-term side effects of chemotherapy exposure. Histopathologically, tumors with remission periods >25 days before recurrence transformed from a "small-round-blue cell" (SBRC) to predominantly "large cell" neuroblastoma (LCN) histopathology, a more aggressive tumor subtype with unfavorable clinical outcomes. These results show that intratumoral chemotherapy delivery may be a treatment strategy for pediatric neuroblastoma, potentially translatable to other focal tumors types. Furthermore, this treatment modality allows for a clinically relevant mouse model of tumor transformation that may be used for studying the phenotypical tumor ...

      Read Full Article
    20. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.

      "Treatment with JQ1 blocked the recruitment of Nrf2 to the antioxidant responsive elements at Nrf2 target gene promoters, and JQ1 exerted synergistic anticancer effects with nanaomycin by blocking the Nrf2-antioxidant signaling pathway. JQ1 and vincristine synergistically induced neuroblastoma cell cycle arrest at the G2/M phase, aberrant mitotic spindle assembly formation and apoptosis, but showed no effect on cell survival in normal non-malignant cells. Importantly, co-treatment with JQ1 and vincristine synergistically suppressed tumor progression in neuroblastoma-bearing mice. These results strongly suggest that patients treated with BET bromodomain inhibitors in clinical trials should be co-treated with vincristine."

      Read Full Article
      Mentions: Treatment
    1-24 of 306 1 2 3 4 ... 11 12 13 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) ALK
    2. (1 articles) MYCN
  4. General Informations in the News

    1. (2 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Chemotherapy